Stocks making the biggest moves midday: Rogers, United Therapeutics, Moderna, FormFactor & more

Rogers rose 10% on higher earnings guidance ($3.80 vs. $3.65 consensus). Liquidia fell 25% after a patent infringement ruling, while United Therapeutics gained 15%. Jabil dropped 7% despite beating earnings and revenue estimates. Concentrix climbed 5% on strong earnings but issued weak guidance. Moderna fell 7% after a Citi downgrade. FormFactor gained 8% on a Deutsche Bank buy rating. Cal-Maine Foods declined 2% on a wider-than-expected loss.

Original reporting
Published Sep 30, 2026, 5:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 5:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stocks making the biggest moves midday: Rogers, United Therapeutics, Moderna, FormFactor & more — source image
Decision brief

The 30-second read

$LQDABearishMed
01

Why it matters

The article aggregates multiple independent catalysts, providing traders with a quick scan of actionable events across sectors.

02

Market read

Multiple stocks experienced notable price moves due to fresh earnings, legal rulings, and analyst actions, offering short‑term trading ideas.

03

What to watch

Potential downstream effects of the patent ruling on other biotech firms and supply‑chain considerations for FormFactor.

Relevance 7/10Novelty 6/10Timing: midday today

Background

A midday roundup highlighting the biggest stock moves, each driven by distinct corporate news items.

Company-level read

Ticker impact

$LQDABearishHigh confidence
Context

Liquidia shares plunged ~25% after a Delaware court ruled it infringed United Therapeutics patents.

Expected impact

likely pressure as the market prices in the adverse legal outcome

Evidence & confidence

Court ruling is a material legal setback; shares already fell sharply.

$UTHRBullishHigh confidence
Context

United Therapeutics surged ~15% following the same court decision that favored its patent claims.

Expected impact

likely upside as investors reward the favorable legal outcome

Evidence & confidence

Legal win removes uncertainty and could boost licensing opportunities.

$JBLBearishMedium confidence
Context

Jabil fell >7% despite beating Q4 earnings, after reporting revenue and EPS that exceeded expectations.

Expected impact

potential continued pressure as market digests unclear guidance

Evidence & confidence

Price drop indicates investors may be wary of future outlook despite current beat.

$CNXCNeutralMedium confidence
Context

Concentrix rose 5% after reporting Q3 adjusted earnings above expectations, but revenue guidance missed estimates.

Expected impact

moderate upside as the earnings beat may outweigh guidance miss

Evidence & confidence

Investors weigh strong earnings against weaker guidance.

$MRNABearishHigh confidence
Context

Moderna fell 7% after Citi downgraded the stock to sell, citing a price target 60% below the current price.

Expected impact

likely pressure as the downgrade may trigger sell orders

Evidence & confidence

Downgrade with a large price target gap is a strong bearish signal.

$FORMBullishHigh confidence
Context

FormFactor shares rose 8% after Deutsche Bank initiated coverage with a buy rating, citing its role as a second source of probe cards for Nvidia GPUs.

Expected impact

likely upside as coverage may attract new buyers

Evidence & confidence

Analyst buy rating and strategic relevance support price gains.

$CALMBearishMedium confidence
Context

Cal-Maine Foods slid 2% after reporting a wider-than-expected Q1 loss of $1.26 per share versus $0.77 expected.

Expected impact

slight pressure as the loss beat expectations

Evidence & confidence

Loss miss may cause short‑term sell pressure.

Market effects

Legal outcomes for biotech (Liquidia, United Therapeutics) and earnings beats/misses for tech and consumer services may shift sector sentiment.

U.S. equities impacted across multiple sectors during midday trading.

Limited to U.S. markets; no broader macro or geopolitical effect.

Counterpoint

Some investors may view the legal win for United Therapeutics as a short‑term rally, but the broader biotech risk remains high.

Key entities

  • Liquidia

    Biotech firm facing patent infringement ruling.

  • United Therapeutics

    Biotech firm benefiting from patent ruling.

  • Jabil

    Electronics manufacturer reporting Q4 earnings beat.

  • Concentrix

    Business services firm with earnings beat but weak guidance.

  • Moderna

    Pharma company downgraded by Citi.

Related articles

$MRNAMed

Why is Moderna stock sliding today?

Moderna (MRNA) shares fell 3.8% to $212.50 as investors reassess its valuation after its 2026 Analyst Day. The company projected higher cash costs and deferred 2027 revenue guidance, disappointing investors. A norovirus vaccine trial also failed to meet early success criteria. Insider stock sales and a weak market for growth equities added to the pressure, though Moderna will be added to the MSCI World Index on November 30.

$MRNAMed

Moderna Sinks 12% in a Week. Bancel Wants an FDA Filing “Before the End of the Year”

Moderna (MRNA) fell 12% in the week to Nov. 13 after projecting $4B+ annual costs through 2030, primarily for cancer drug development, including intismeran with Merck (MRK). CEO Bancel aims for FDA filing by year-end. Analysts' 2028 revenue estimates are below annual costs, and the stock trades at a high sales multiple. BioNTech (BNTX), a rival, expects revenue to fall 35.4% this year.

$MRKMedAI 9/10

He Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental Treatment

Merck (MRK) and Moderna (MRNA) reported a Phase 3 trial where a personalized vaccine, combined with Keytruda, kept 82.2% of melanoma patients cancer-free for two years, compared to 70.0% with Keytruda alone. The vaccine is not yet FDA-approved, so Medicare does not cover it outside of clinical trials. Patients may face out-of-pocket costs for trial participation.

$MRNALow

Exclusive: Moderna RSV Vaccine Trial in Babies Linked to Severe RSV, Other Serious Injuries

Moderna halted its clinical trial for two experimental infant RSV vaccines in July 2024 after higher severe RSV rates in vaccinated babies. U.K. regulators reported 13 serious adverse reactions. Researchers found lung inflammation in preclinical data, suggesting Moderna downplayed safety signals. The FDA approved the trial without consulting advisers, raising oversight questions. Moderna extended the trial's end date to 2029, delaying final outcome reports.